CAR-T In Vitro Efficacy Services with OncoSolid™ Prostate Cancer Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Prostate Cancer Organoid Models

Prostate cancer (PCa) is one of the most malignant tumors among men, which presents a high heterogeneity and incidence rate around the world. Relapse and resistance often occur after current treatment and progress to neuroendocrine carcinoma or metastasis to other organs. There is an urgent need to increase the knowledge of pathogenesis and complex heterogeneity to enhance the development of promising drugs and therapies for patients. Cancer organoid is a powerful 3d culture that recapitulates the key features of clinical tumor tissue and allows genetic manipulation to study the mechanism of origin. Moreover, the organoid is a proper model for in vitro large-scale screening and tests.

Fig.1 Establish prostate cancer organoids from different pathways for various applications. (Zhou, et al., 2021)

Workflow

Key Features

Workflow

Reflect the biological characteristics and clinical diversity of PCa, Retain the heterogeneity of primary tumor tissues in vitro well, A large biobank of prostate cancer organoids reflecting diverse tumor tissue, Enables high-throughput analysis of drugs and immunotherapies.

Organoid Culture Conditions

Optimal culture media for each tumor tissue with different sources and genetic backgrounds
Improved generation of cancer organoids from tumor epithelial cells without normal basal cells

Necessary Compounds and Growth Factors
Epidermal growth factor (EGF)	Dihydrotestosterone (DHT)	R-spondin-1	Anaplastic lymphoma kinase (ALK) inhibitor
Fibroblast growth factor-2 (FGF2)	Prostaglandin E2 (PGE2)	Nicotinamide	Fibroblast growth factor-10 (FGF10)
Rho kinase inhibitor	Noggin	B27 supplement	N-acetylcysteine
P38 inhibitor

Subtypes of Prostate Cancer Organoids

Cancer organoids can be generated from multiple phenotypes of prostate cancers using different sources of tumor cells.

Tumor at Any Stage of Development

Primary tumor organoid model
Metastatic prostate cancer organoid model
Castration resistant prostate cancer organoid model
PCa-Neuroendocrine organoid model

Various Sources

Human
iPSCs (Induced pluripotent stem cells)
hESCs (Human embryonic stem cells)
Patient derived tumor biopsy
Tumor cell lines (LNCaP, C4-2B))
Mouse
PDX (Patient derived xenograft)
GEMM (Genetically engineered mouse model)

Diverse Clinical Reported Gene Mutations in Prostate Cancer
TMPRSS2-ERG	ETS	SPOP	SPINK1	FOXA1
PIK3R1	CHD1	PTEN	Androgen receptor

Characterization of Established Organoids

	Description	Technique
Phenotype Characterization	Growth pattern Histological structure Morphology Cell components	Immunohistochemistry (IHC) Immunofluorescence (IF) Fluorescence in situ hybridization (FISH)
Molecular Characterization	Copy-number aberrations (CNA) Disease related gene mutations Single-nucleotide variants (SNV) Chromosomal rearrangements Karyotype characterization	Whole genome sequencing Whole exome sequencing RNA sequencing Epigenomics Proteomic Analysis

Application of the Prostate Cancer Organoid Models

Study of pathogenesis
Drug screening
Mechanism of clinical treatment resistance
Personalized medicine for PCa
CAR therapy development

Highlights

Short turnaround time, within two weeks for organoids generation
High-throughput assay for drug screening and efficacy test
Advanced data analysis and readout
The full solution provides for the whole process

Prostate Cancer-related CAR-T Products and Services at Creative Biolabs

Creative Biolabs is a leader in CAR-T therapy development. We have extensive CAR-cell therapy-related products and offer customized CAR-T development services for various tumors to clients worldwide.

Target Antigen	Target Description	CAR-T Products
PSCA	PSCA is a prostate cancer-related protein that expresses on the surface of basal and secretory epithelial cells. The protein is also associated with gastric, renal, and pancreatic cancer.	Anti-PSCA CAR-T
EpCAM	Epithelial cell adhesion molecule (EpCAM) mediates cell-cell adhesion in epithelia and is relevant to cell growth and metastasis. EpCAM is a potential target for immunotherapy of various solid tumors.	Anti-EpCAM CAR-T
PSMA	Prostate-specific membrane antigen (PSMA) is mainly expressed on prostate cancer cells and serves as a diagnostic biomarker and targeted protein for clinical treatment.	Anti-PSMA CAR-T
PSA	Prostate-specific antigen (PSA) is widely present in normal and cancer cells of prostate tissues, but the concentration is increased in patients' blood with prostate cancer.	Anti-PSA CAR-T
PAP	Prostatic acid phosphatase (PAP) is the secretory glycoprotein from prostate epithelial cells, and the elevated concentration of PAP in human blood indicates prostate cancer and neoplastic hematologic disorder.	Anti-PAP CAR-T

Creative Biolabs has committed to cancer organoid technology and is continually discovering to simulate the tumor features and microenvironment to more extent. If you have trouble with cancer organoids culture and application, please contact us for help.

Reference

Zhou, L.; et al. Application of Organoid Models in Prostate Cancer Research. Frontiers in oncology. 2021, 11: 736431.